Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Finasteride

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Finasteride. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-005418-19 Sponsor Protocol Number: minofina2005 Start Date*: 2006-06-28
    Sponsor Name:Dr. med. Bernd Salzer, Private Praxis
    Full Title: Comparison of the efficiency between Minoxidil 5% or Finasteride 1mg and Minoxidil 5% + Finasteride 1mg in androgenetic alopecia (male pattern) at Hamilton classification scale II - V.
    Medical condition: Alopecia androgenetica
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005809-65 Sponsor Protocol Number: UA12 Start Date*: 2006-12-20
    Sponsor Name:Department of pharmacy, Uppsala University
    Full Title: An open, fixed order, single center pharmacokinetic study of the influence of St John's wort on the pharmacokinetics and metabolism of fiansteride in healthy male subjects
    Medical condition: The trial contains only healthy volunteers. The indication for Proscar is benign prostatic hyperplasia and for Movina mild depression.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020604-29 Sponsor Protocol Number: H6D-CR-LVIW(a), Addendum 1 u.4 Start Date*: 2010-11-05
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 3b,randomized,double-blind,placebo-controlled parallel-design study to evaluate the efficacy and safety of tadalafil coadministered with finasteride for 6 months in men with lower urinary ...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed) BE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002877-40 Sponsor Protocol Number: PM1541 Start Date*: Information not available in EudraCT
    Sponsor Name:Polichem S.A.
    Full Title: A multicentre, randomized, double-blind, parallel-group, controlled study, to assess the efficacy and safety of P-3074 cutaneous spray, solution, in the treatment of male pattern baldness.
    Medical condition: Androgenetic alopecia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10068168 Androgenetic alopecia PT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed) HU (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000502-19 Sponsor Protocol Number: PSY-NIL-0002 Start Date*: 2016-06-21
    Sponsor Name:Medical University of Vienna, Department of Psychiatry and Psychotherapy
    Full Title: Effects of sex steroid hormones on serotonin synthesis and degradation measured with PET
    Medical condition: Gender Dysphoria (Female-to-male transsexuals and male-to-female transsexuals)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001365-32 Sponsor Protocol Number: 19CX5006 Start Date*: 2019-07-25
    Sponsor Name:Imperial Joint Research Compliance Office
    Full Title: IP4- CHRONOS: Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001186 Adenocarcinoma of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-000612-26 Sponsor Protocol Number: FINTOURPARK Start Date*: 2011-09-19
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
    Full Title: Open-label study on the use of Finasteride in prolonged treatment (4 years) of tics in Tourette's disease and Parkinson's disease in the pounding
    Medical condition: Syndrome Gilles de la Tourette's disease Parkinosn Pounding
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003177-26 Sponsor Protocol Number: RT2019-13 Start Date*: 2020-02-05
    Sponsor Name:UMCG
    Full Title: Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy
    Medical condition: Patients with biochemical recurrence after primary treatment of prostate cancer presenting with ≤4 metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004321-15 Sponsor Protocol Number: H6D-MC-LVHK(b) Start Date*: 2007-12-14
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign P...
    Medical condition: Effects on urodynamic parameters in men with benign prostatic hyperplasia (also referred to as BPH-LUTS [lower urinary tract symptoms]) with and without urodynamic evidence of bladder outlet obstru...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002841-21 Sponsor Protocol Number: H6D-MC-LVHJ(a) Start Date*: 2008-10-28
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of B...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004322-24 Sponsor Protocol Number: ARN-509-003 Start Date*: 2013-08-27
    Sponsor Name:Aragon Pharmaceuticals, Inc
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
    Medical condition: Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Ongoing) FI (Completed) SE (Completed) NL (Trial now transitioned) BE (Trial now transitioned) IT (Ongoing) NO (Completed) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) DK (Ongoing) HU (Ongoing) CZ (Trial now transitioned) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010739-42 Sponsor Protocol Number: H6D-MC-LVID Start Date*: 2009-10-01
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men with Signs ...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) NL (Completed) BE (Completed) AT (Completed) IT (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-001958-27 Sponsor Protocol Number: H6D-MC-LVHG Start Date*: 2006-07-13
    Sponsor Name:Lilly ICOS LLC
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men ...
    Medical condition: Primary treatment of the signs and symptoms of benign prostatic hyperplasia in men (also referred to as BPH-LUTS [lower urinary tract symptoms]). BPH-LUTS include urinary frequency, urgency, interm...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020220-22 Sponsor Protocol Number: H6D-MC-LVIR Start Date*: 2010-12-21
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men with Signs and Symptoms of Be...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-018191-34 Sponsor Protocol Number: FOL003 Start Date*: 2010-07-21
    Sponsor Name:Follica Inc.
    Full Title: A Study to Explore the Effect of Controlled Cutaneous Perturbation and Pharmacologic Modulation for Inducing Follicular Neogenesis
    Medical condition: Male subjects with androgenetic alopecia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10068168 Androgenetic alopecia LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003314-97 Sponsor Protocol Number: CA184-043 Start Date*: 2009-08-05
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Do...
    Medical condition: Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) AT (Completed) NL (Completed) IT (Completed) CZ (Completed) DK (Completed) ES (Completed) IE (Completed) BE (Completed) GB (Completed) HU (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022255-37 Sponsor Protocol Number: CHUBX2010/39 Start Date*: 2010-09-29
    Sponsor Name:CHU de Bordeaux
    Full Title: Etude de l’efficacité et de la tolérance, de l’injection intra prostatique de toxine botulique A, chez l’homme, dans le traitement de l’hyperplasie bénigne de prostate symptomatique.
    Medical condition: HBP symptomatique modérée à sévère selon le score IPSS
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020728 Hyperplasia of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001128-31 Sponsor Protocol Number: 13-23 Start Date*: 2014-09-23
    Sponsor Name:Cancer Trials Ireland
    Full Title: Phase II Single-arm Study evaluating Neo-adjuvant (pre-radical radiotherapy) Abiraterone acetate (plus prednisolone) and Gonadotropin-Releasing Hormone (GnRH) agonist in high risk localised prostat...
    Medical condition: High-risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016800-22 Sponsor Protocol Number: I1A-MC-BPAE Start Date*: 2010-05-14
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (B...
    Medical condition: Benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004337-25 Sponsor Protocol Number: H6D-MC-LVHR Start Date*: 2009-01-19
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil 2.5 and 5 mg Once Daily Dosing for 12 Weeks for the Treatment o...
    Medical condition: Benign prostatic hyperplasia and erectile dysfunction.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061461 LLT
    9.1 10004446 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed) PT (Completed) DE (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:11:22 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA